Surrogate Endpoints Acceptable in AML Trials, Says FDA

In the case of drugs used for newly diagnosed acute myeloid leukemia (AML), surrogate endpoints have been validated, says the US Food and Drug Administration.
Medscape Medical News

source https://www.medscape.com/viewarticle/967529?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost